Proven anti-anxiety peptide versus its potential next-generation successor – same family of compounds, but a completely different level of scientific evidence
What is Adalank and how does it relate to Selank?
Adalene can be described as „Selank 2.0” – a newer, modified version of the same compound. Both peptides were developed at the same Russian research institute and are derived from the same natural molecule – fuzz, which participates in communication between the immune and nervous systems.
The creators of Adalank made minor modifications to Selank's structure to potentially increase its stability in the body, improve its targeting in the brain, or prolong the duration of action of a single dose.
The most important difference, however, concerns the amount of available scientific data. Selank is a well-studied and approved medicine, whose efficacy has been assessed in over 15 clinical trials in humans. Adalank The compound is currently in the experimental research stage – almost all available data comes from animal studies. It has not been approved in any country and no significant human clinical trials have been published. Therefore, both compounds are at completely different stages of development.
What are the differences in terms of construction and operational durability?
| Feature | Selank | Adalank |
|---|---|---|
| Peptide structure | 7 amino acids; structure fully described and well-documented | Also based on tuftsine, but it includes modifications intended to potentially slow down its breakdown in the body; the exact structure has not been widely published in international literature. |
| Stability in the body | The parent molecule breaks down after about 2 minutes, but active fragments can persist for 3–4 hours | Probably more stable according to design intent, which could reduce dosing frequency, however this has not been confirmed in humans |
| Method of administration | Nasal spray (0.15% solution) with fixed dosing regimens | Presumably also administered intranasally, but official dosing in humans has not been established |
How do they affect the brain?
| Feature | Selank | Adalank |
|---|---|---|
| Regulation of the nervous system | Gently supports the natural GABA-based inhibitory system without the risk of sedation and addiction characteristic of classic sedatives; confirmed in clinical studies | It probably works in a similar way, however, preliminary data suggest a more selective impact on the GABA system and potentially an even smaller risk of sedation; the data are exclusively from preclinical studies |
| Protection and development of nerve cells | Well-documented impact on increasing BDNF and NGF, supporting memory and learning | Animal data suggest similar or potentially stronger neuroprotective effects; one rodent study demonstrated better brain tissue protection following an ischaemic-like episode. |
| Effect on mood | A mild effect on serotonin and dopamine pathways, which may translate into subtle mood-enhancing effects. | It could be more targeted at reducing anxiety and have less impact on mood; the data is still very limited. |
| Impact on the immune system | Distinct immunomodulatory properties arising from its tuftsin origin | As the basic structure of tuftsin has been preserved, similar effects are expected, however, this has not yet been investigated. |
| Stress resistance | It slows down the decomposition of natural substances that support emotional stability, increasing resistance to stress. | It likely shows a similar effect due to retaining the basic structure, however, there is a lack of specific research for Adalank |
What Do the Studies Show?
| Feature | Selank | Adalank |
|---|---|---|
| Human research | Around 15 clinical trials in Russia and Ukraine; significant reduction in anxiety was demonstrated in individuals with anxiety disorders and stress-related problems | Practically no published clinical studies in humans; single preliminary reports have not been more widely published in international literature. |
| Animal testing | Extensive; confirm influence on neuroprotection, GABA regulation, neurotransmitter systems and immune system | A moderate number of studies; in standard rodent anxiety models, Adalank showed comparable or slightly stronger effects than Selank. |
| Safety profile | Good tolerability in all published clinical studies; no serious adverse events; limited data on long-term use | No safety data in humans; toxicological results in animals are promising but do not replace clinical trials |
| Regulatory status | Approved in Russia and Ukraine for use in anxiety and stress-related fatigue | Not approved in any country; not yet at the stage of applying for registration |
| Dosage | Established: 400–600 micrograms intranasally, 1–3 times daily | There is no validated dosage for humans; any use is experimental. |
| Availability | Commercial product in Russia and Ukraine; otherwise, mainly available as a research peptide | For research purposes only; very limited availability |
Potential Advantages and Limitations
What could Adala potentially improve compared to Selank?
If structural modifications prove effective in humans, Adalank could offer:
- longer duration of action and less frequent dosing,
- more selective anxiolytic action,
- Even lower risk of sedation,
- stronger neuroprotective properties,
- maintaining beneficial immunomodulatory properties.
However, it should be emphasised that these are design assumptions, which have not yet been confirmed in human clinical trials.
Why is Selank Currently a Safer Choice?
Selank possesses:
- proven clinical efficacy,
- well-known security profile,
- established dosing schedules,
- approval for use in Russia and Ukraine.
Adalank, on the other hand:
- it does not have data on pharmacokinetics in humans,
- There is no established dosage.,
- does not have clinical safety data,
- has not been adequately studied in humans.
At the current stage, it should be treated solely as experimental research compound.
What Research Is Still Needed?
| Area | Selank | Adalank |
|---|---|---|
| Most urgent research needs | Replication of Russian studies compliant with international standards and long-term safety studies exceeding 6 months | The first human studies to determine safety, dosage and pharmacokinetics |
| Comparative studies are needed | Direct comparisons with SSRIs and Afobazole to determine its place among available therapeutic options | Direct comparison with Selank in humans, as Adalank was designed as its potential improvement |
| Mechanistic locks | Minor gaps in receptor adaptation during long-term use | Confirmation of greater selectivity towards the GABA system and increased stability, which are currently based solely on preclinical data |
Selank It is a verified and approved preparation with a solid foundation of clinical research in humans. Adalank represents a promising development along the same line of research, but currently remains only at the laboratory stage.
The choice of Adalank over Selank can be likened to choosing a prototype car over a model that has already undergone road testing – the prototype may look promising on paper, but there is still a lack of data to confirm that it will actually meet the expectations placed upon it.
Disclaimer
The content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional before starting, stopping, or changing the use of any medication or supplement.
Ani Selank, and Adalank have not been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or most other Western regulatory bodies. In particular Adalank has not been approved in any country and has no established safety or dosage data in humans..
Most of the studies cited originate from Russia and Ukraine. While presented in good faith, these findings have not been independently verified or replicated by Western regulatory bodies and should be interpreted with appropriate caution.